AxoGen (NASDAQ:AXGN) Announces Earnings Results

AxoGen (NASDAQ:AXGN) posted its quarterly earnings data on Tuesday. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.03), Zacks reports. AxoGen had a negative return on equity of 14.91% and a negative net margin of 7.91%. AxoGen updated its FY 2025 guidance to EPS.

AxoGen Price Performance

NASDAQ:AXGN opened at $18.01 on Tuesday. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. AxoGen has a one year low of $5.55 and a one year high of $19.19. The stock has a 50-day simple moving average of $17.36 and a 200 day simple moving average of $14.87.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group raised their price target on shares of AxoGen from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.